Seeking Alpha
28 Jul 2026, 06:38 UTC · 8w ago
Verdict
Headline leans bullish. We score GMAB +0.80 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
DARZALEX H1 sales reached $8.17B, putting Genmab on track to exceed the high end of its $16.0B–$16.4B full-year guidance.
More positive than 92% of claims this week
A buy rating was issued for Genmab with a 12-month price target of $36, implying 25% upside.
So whatAnalyst upgrades and significant price target premiums provide a positive catalyst for investor sentiment.
Continue reading
5 related stories
More positive than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company has a buy rating with significant upside potential and strong sales performance for DARZALEX exceeding guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+20.3%
Price agrees with the score
$34.63 vs $28.80 close before publication (Jul 27) · not market-adjusted
GMAB chart →
